Expert Opinion on Biological Therapy, Volume 22, Issue 10 (2022)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Biological Therapy, Volume 22, Issue 10 (2022)

See all volumes and issues
Vol 24, 2024 Vol 23, 2023 Volume 22, 2022 Vol 21, 2021 Vol 20, 2020 Vol 19, 2019 Vol 18, 2018 Vol 17, 2017 Vol 16, 2016 Vol 15, 2015 Vol 14, 2014 Vol 13, 2013 Vol 12, 2012 Vol 11, 2011 Vol 10, 2010 Vol 9, 2009 Vol 8, 2008 Vol 7, 2007 Vol 6, 2006 Vol 5, 2005 Vol 4, 2004 Vol 3, 2003 Vol 2, 2002 Vol 1, 2001
Download citations Download PDFs Download issue

Editorial

Editorial
Personalizing immunotherapy for renal cell carcinoma: how far have we come?
Francesco Massari & Veronica Mollica
Pages: 1221-1225
Published online: 09 Sep 2022
First Page PreviewforPersonalizing immunotherapy for renal cell carcinoma: how far have we come? | Full Text | References | PDF (838.6 KB) | EPUB
  • 1048 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Article
Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors
Mifen Chen, Mengyun Jiang, Xinhui Wang, Lin Shen & Jian Li
Pages: 1227-1232
Published online: 20 Sep 2022
AbstractforEnvafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors | Full Text | References | PDF (302.6 KB) | EPUB
  • 3117 Views
  • 1 CrossRef citations
  • 0Altmetric
Open Access

Review

Review
Signaling new therapeutic opportunities: cytokines in prostate cancer
Elias Chandran, Luke Meininger, Fatima Karzai & Ravi A Madan
Pages: 1233-1243
Published online: 08 Aug 2022
AbstractforSignaling new therapeutic opportunities: cytokines in prostate cancer | Full Text | References | PDF (303.3 KB) | EPUB
  • 405 Views
  • 1 CrossRef citations
  • 0Altmetric
Review
Biologics in rectal cancer
Alexandre A Jácome, Renata D’Alpino Peixoto, Mariana V Gil, Juliana Ominelli, Gabriel Prolla, Rodrigo Dienstmann & Cathy Eng
Pages: 1245-1257
Published online: 03 Aug 2022
AbstractforBiologics in rectal cancer | Full Text | References | PDF (448.6 KB) | EPUB
  • 218 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
Eugenia Cella, Lodovica Zullo, Silvia Marconi, Giovanni Rossi, Simona Coco, Chiara Dellepiane, Angela Alama, Leslie Rozeboom, Elisa Bennicelli, Francesca Parisi, Gianluca Sacco, Giulia Barletta, Linda Zinoli, Marco Tagliamento, Paolo Pronzato & Carlo Genova
Pages: 1259-1273
Published online: 28 Aug 2022
AbstractforImmunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives | Full Text | References | PDF (793 KB) | EPUB
  • 445 Views
  • 2 CrossRef citations
  • 0Altmetric
Review
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
Gunay Uludag, Muhammad Hassan, Wataru Matsumiya, Brandon Huy Pham, Sophaktra Chea, Ngoc Trong Tuong Than, Hien Luong Doan, Amir Akhavanrezayat, Muhammad Sohail Halim, Diana V Do & Quan Dong Nguyen
Pages: 1275-1291
Published online: 17 Jul 2022
AbstractforEfficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? | Full Text | References | PDF (1.7 MB) | EPUB
  • 960 Views
  • 1 CrossRef citations
  • 0Altmetric
Review
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)
Ronak Patel, Pravin Ghadge, Pravin A. Nair, Manish Kumar & Laxmi Adhikary
Pages: 1293-1310
Published online: 18 Aug 2022
AbstractforA review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA) | Full Text | References | PDF (997.7 KB) | EPUB | Supplemental
  • 261 Views
  • 0 CrossRef citations
  • 0Altmetric
Review
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis
Alessandra Alciati, Marco Di Carlo, Cesare Siragusano, Antonino Palumbo, Ignazio Francesco Masala & Fabiola Atzeni
Pages: 1311-1322
Published online: 14 Oct 2022
AbstractforEffect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis | Full Text | References | PDF (913.4 KB) | EPUB
  • 400 Views
  • 1 CrossRef citations
  • 0Altmetric

Original Research

Article
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia
Soamarat Vilaiyuk, Butsabong Lerkvaleekul, Janejira Jino, Sirirat Charuvanij, Yun Xin Book & Thaschawee Arkachaisri
Pages: 1323-1332
Published online: 27 Jul 2022
AbstractforComparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia | Full Text | References | PDF (3 MB) | EPUB | Supplemental
  • 170 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles